Reuters
02 Oct 2025, 19:37 UTC · 50w ago
Verdict
Headline leans bullish. We score JAZZ +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
The FDA expanded approval for Jazz Pharmaceuticals' therapy as a maintenance treatment for adult patients with a type of lung cancer.
More positive than 96% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of ticker scores this week
The FDA expanded the approval for one of the company's therapies, opening a larger patient market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1d ago
+75.3%
Price agrees with the score
$240.00 vs $136.90 close before publication (Oct 1) · not market-adjusted
JAZZ chart →
